NCT03092635 is a Phase 1 clinical trial of OPC in Breast Cancer, sponsored by Medical University of South Carolina.

Who is sponsoring NCT03092635?

NCT03092635 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT03092635?

Interventions in NCT03092635: OPC.

What condition does NCT03092635 study?

NCT03092635 studies Breast Cancer.

Is NCT03092635 still recruiting?

NCT03092635 is currently terminated. Last updated 6 January 2025.

Last reviewed 2025-01-06 · How we verify

NCT03092635

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Terminated Phase 1 Last updated 6 January 2025

What this trial tests

Phase 1 trial testing OPC in Breast Cancer in 9 participants. Terminated before completion.

Timeline

6 June 2017

Primary endpoint
10 November 2021

22 April 2022

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	6 June 2017
Primary completion	10 November 2021
Estimated completion	22 April 2022
Sites	1 location across United States

Drugs / interventions tested

OPC — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Medical University of South Carolina

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to look at the effects that the study drug (OPC) has on AGE levels in patients with ER+ metastatic breast cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy.
Vella V, Lappano R, Bonavita E, Maggiolini M, et al · · 2023 · cited 38× · PMID 36869790 · DOI 10.1210/endrev/bnad005
RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
Muoio MG, Pellegrino M, Rapicavoli V, Talia M, et al · · 2023 · cited 6× · PMID 37461077 · DOI 10.1186/s13058-023-01686-5
Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider.
Rojas A, Lindner C, Schneider I, Gonzàlez I, et al · · 2022 · cited 1× · PMID 36338887 · DOI 10.3748/wjg.v28.i39.5679

Verify or expand the search:

Other trials of OPC

Trials testing the same drug.

NCT02946996 — Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving · Phase 2 · terminated

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03092635 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 6 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing